• Home
  • » 
  • Reports
  • » 
  • Subcutaneous Biologics, Technologies and Drug Delivery Systems (2nd Edition) | Industry Analysis | Market Size | 2030

Subcutaneous Biologics, Technologies and Drug Delivery Systems (2nd Edition), 2018-2030

  • Lowest Price Guaranteed From USD 3,499

  • Published
    June 2018

  • Pages
    401

  • View Count
    8500

  • Buy Now

Example Insights

An updated edition is available at the following link

View 3rd edition

Subcutaneous Biologics, Technologies and Drug Delivery Systems Companies Subcutaneous Biologics, Technologies and Drug Delivery Systems Market Overview Subcutaneous Biologics, Technologies and Drug Delivery System Market Overview
Subcutaneous Biologics, Technologies and Drug Delivery Systems Subcutaneous Biologics, Technologies and Drug Delivery Systems Techonology Providers
Subcutaneous Biologics, Technologies and Drug Delivery Systems Product Competitveness Subcutaneous Biologics, Technologies and Drug Delivery Systems Market Forecast Subcutaneous Biologics, Technologies and Drug Delivery System Market Forecast

 

Report Description

The industry is expected to witness significant growth over the coming decade. Part of this may be driven by smaller biologics and companies focusing on oral bioavailability. However, for larger molecules, there is likely to be a significant push towards subcutaneous delivery and many companies are expected to be built around this in the coming years

-Chief Executive Officer, a US based biopharma company

Biologics constitute a majority of the top selling drugs of today and also represent one of the fastest growing segments of the overall pharmaceutical industry. In fact, the share of biologics in the overall pharmaceutical market has increased from 16% in 2006 to over 25% in 2017.Having reported over 70% increase in revenues over the past 5-6 years, the market for biologically derived products is currently estimated to be worth more than USD 200 billion.Despite their clinical and commercial success, biopharmaceutical products are associated with high development costs, which are evidently reflected in their prices. Moreover, such therapies are usually designed for intravenous administration, which require a clinical setting (hospitals / infusion centers) for dosing; this further adds to the overall treatment cost. Of late, the subcutaneous route of administration has emerged as a promising and viable approach for the parenteral delivery of biologic drugs. Owing to several compelling advantages, such as patient convenience, potential for self-administration, better therapy adherence and reduced healthcare costs, the concept is steadily gaining traction within the healthcare industry.

Given the robust pipeline of biologics, which include monoclonal antibodies, vaccines and other protein-based therapeutic products, subcutaneous delivery options are being investigated for various clinical candidates across different phases of development. In fact, several approved therapeutic products that are currently delivered intravenously are also being reformulated and evaluated for subcutaneous administration in order to improve their adoption, and for life cycle management of drugs nearing patent expiry.

In addition, several drug delivery devices that can be used for self-administration have been developed, and many others are under development. Some of the most popular self-administration enabling devices include large volume wearable injectors, autoinjectors, pen injectors, needle free injectors and prefilled syringes. In fact, these innovative drug-device combination products have witnessed high adoption rates over the past few years and have brought about marked improvements in adherence to prescribed therapeutic regimens. Further, to overcome the limitations and challenges associated with the delivery of subcutaneous formulations, several novel technology platforms have been developed to enable the delivery of (highly) viscous formulations. The rising incidence of chronic clinical conditions (which are characterized by the need for frequent medications) and continuous efforts of therapy / device developers in this field are anticipated to drive the overall growth of this market in the coming years.

 

Scope of the Reoprt

The ‘Subcutaneous Biologics, Technologies and Drug Delivery Systems (2nd Edition), 2018-2030’ report provides a comprehensive study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle free injectors, prefilled syringes, drug reconstitution systems and implants) that enable subcutaneous delivery of the aforementioned drugs. Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape of commercially available biologics that are designed for delivery via the subcutaneous route, along with information on the developer(s), type of molecule, target indication / therapeutic area, approval year, dose strength, treatment regimen and available dosage forms. The study also includes comprehensive case studies on leading subcutaneous biologics, featuring details on annual sales, mechanisms of action, development histories, technology platforms (if available), and a comparison of their intravenous and subcutaneous formulations (if applicable).
  • An in-depth analysis of the various subcutaneous biologics that are currently under clinical development, with information on the developer(s), phase of development, type of molecule, and target therapeutic area.
  • A review of various innovative technology platforms that are used for the formulation of drugs for subcutaneous delivery, highlighting their key features and providing information on their developers, mechanisms of action and advantages. The study also includes an insightful three-dimensional analysis of the technology platforms that are presently engaged in developing drug formulations for subcutaneous delivery, comparing them based on pipeline strength (in terms of marketed / under development drugs based on the technology), supplier power (in terms of year of establishment and size of employee base) of the developer and number of collaborations established related to the technology.
  • A detailed benchmark analysis of technology providers that are based in North America and Europe, highlighting the advantage(s) of their proprietary technology platforms, applicability to other types of molecules, and other possible modes of drug delivery.
  • Elaborate profiles of key technology providers, featuring overview of the companies, a review of their proprietary technologies, mechanisms of action, key advantages, list of product candidates developed using the technology, recent developments related to the technology (funding and collaborations) and a comprehensive future outlook.
  • An in-depth review of the most advanced and popular subcutaneous drug delivery systems, focused on large volume wearable injectors, autoinjectors, pen injectors, needle free injectors, prefilled syringes, drug reconstitution systems and implants, providing information on their developer(s) and device specifications / features. Details of specific parameters captured for different device categories are mentioned as follows:
  • Large volume wearable injectors: Type of device (infusion pump and patch pump), type of dose delivered (continuous and bolus), volume of drug container / storage capacity (in mL), usability (disposable and reusable) and stage of development (commercialized and under development).
  • Autoinjectors: Type of drug container (syringe, cartridge and others), usability (disposable and reusable), mechanism of action (automatic, semi-automatic and manual), volume of the drug container (in mL) and dosage type (fixed dose and variable dose).
  • Pen injectors: Usability (disposable and reusable), volume of the drug container (in mL) and dosage type (fixed dose and variable dose).
  • Needle free injection systems: Type of technology (jet, spring and gas), usability (disposable and reusable) and drug volume delivered (in mL).
  • Prefilled syringes: Type of syringe (glass and plastic).
  • Drug reconstitution systems: Type of device (dual chambered systems and other novel systems), type of container (cartridge and others) and usability (disposable and reusable).
  • Implants: Type of material (silicone, titanium, polymers and others), target therapeutic indication, type of implant (biodegradable and non-biodegradable), treatment duration, type of drug delivered, dose strength and stage of development.
  • A comprehensive product competitiveness analysis of large volume wearable injectors and subcutaneous autoinjectors taking into consideration the supplier power (based on size of employee base) and product specifications.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework. The analysis features a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall subcutaneous products market.

One of the key objectives of this study was to understand the primary growth drivers and estimate the future potential of the market. Based on historical trends and sales related information for subcutaneous biologic drugs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. In addition, we have segmented the market based on [A] therapeutic areas (autoimmune disorders, metabolic disorders, blood disorders, bone disorders, oncological disorders, genetic disorders, neurological disorders, respiratory disorders and others) and [B] molecule type (proteins, peptides (recombinant), monoclonal antibodies, other antibody based products, cell / gene therapies and vaccines). In addition to the market forecast for subcutaneous biologic drugs, we have also provided an 8-year forecast for subcutaneous delivery systems, covering large volume wearable injectors, autoinjectors, prefilled syringes and drug reconstitution systems. Further, we have also forecasted the revenues that subcutaneous formulation technology developers are likely to generate through licensing agreements; for this, we have provided a view on the likely upfront payments and milestone payments that will be involved in the deals signed or planned with an aim to develop subcutaneous formulation of biologics. To account for the uncertainties associated with the growth of the subcutaneous formulation technologies market, we have provided three forecast scenarios, portraying conservative, base and optimistic tracks of the market’s evolution.

The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered both from secondary and primary sources. This enabled us to solicit inputs on upcoming opportunities and challenges that were considered to develop estimates for a more inclusive growth. The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • David Daily (Chief Executive Officer & Co-Founder, DALI Medical Devices)
  • Deborah Bitterfield (Chief Executive Officer and Founder, Lindy Biosciences)
  • Frederic Ors (Chief Executive Officer, Immunovaccine Technologies)
  • Matthew Young (Founder & Chief Technology Officer, Oval Medical Technologies)
  • Menachem Zucker (Vice President & Chief Scientist, Elcam Medical)
  • Michael Reilly (Chief Executive Officer & Co-Founder, Excelse Bio)
  • Michael Hooven (Chief Executive Officer, Enable Injections)
  • Poonam R Velagaleti (Co-Founder, i-novion)
  • Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) and Graham Reynolds (Vice President & General Manager, Global Biologics, West Pharmaceutical Services)
  • David Heuzé (Communication Leader, MedinCell)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  provides an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of subcutaneous products market, in the short-mid-term and long term.

Chapter 3  provides a general introduction to the various types of therapeutic molecules (biologics and small molecules) comparing their characteristics such as size, structure, immunogenicity and stability. The chapter also highlights different types of biologically derived products that are currently being developed. Further, the chapter features a discussion on the different routes of administration, specifically focusing on the subcutaneous route, highlighting its advantages and associated limitations.

Chapter 4  includes information on over 330 subcutaneous biologic drug candidates that are currently approved / under development. It features a comprehensive analysis of marketed molecules based on the type of molecule, target indication, target therapeutic area, approval year, dose strength, treatment regimen and available dosage forms. On the other hand, pipeline molecules have been analyzed based on parameters such as type of molecule, target indication and target therapeutic area.

Chapter 5  is a collection of comprehensive case studies on the leading subcutaneous biologics in terms of annual sales. Each case study includes drug / therapy specifications, their respective mechanisms of action, development histories, target therapeutic indication(s), available dosage forms, historical annual sales, technology platforms ( if available ), and a comparison of intravenous and subcutaneous formulations ( if applicable ).

Chapter 6  provides a list of subcutaneous delivery technology platforms that are either currently available, or being developed by various firms, for the formulation of subcutaneous drugs. The chapter highlights key features of each technology and provides information on their developers. It also features an analysis based on the advantage(s) of their proprietary technology platforms, applicability to other types of molecules, and other possible modes of drug delivery.

Chapter 7  features a three-dimensional analysis of the technology platforms that are presently available for developing drug formulations for subcutaneous delivery. The analysis takes into consideration several parameters, such as pipeline strength (in terms of product candidates developed based on the technology, both marketed and under development), supplier power of the developer (in terms of year of establishment and employee size of the company) and number of collaborations established related to the technology, over the past few years. It also includes a benchmark analysis of technology providers that are based in North America and Europe, highlighting the advantage(s) of their proprietary technology platforms, applicability to other types of molecules, and other possible modes of drug delivery.

Chapter 8  includes elaborate profiles of key technology providers, featuring overview of the companies, a review of their proprietary technologies, mechanisms of action, key advantages, list of product candidates developed using the technology, recent developments related to the technology (funding and collaborations) and a comprehensive future outlook.

Chapter 9  features an elaborate discussion on subcutaneous delivery systems with special focus on large volume wearable injectors, autoinjectors, pen injectors, needle free injectors, prefilled syringes, drug reconstitution systems and implants. It includes a detailed analysis based on specific parameters for each device category, namely [A] large volume wearable injectors, by type of device (infusion pump and patch pump), type of dose delivered (continuous and bolus), volume of drug container / storage capacity (in mL), usability (disposable and reusable) and status of development (commercialized and under development), [B] autoinjectors, by type of drug container (syringe, cartridge and others), usability (disposable and reusable), mechanism of action (automatic, semi-automatic and manual), volume of the drug container (in mL) and dosage type (fixed dose and variable dose) [C] pen injectors, by usability (disposable and reusable), volume of the drug container (in mL) and dosage type (fixed dose and variable dose) [D] needle free injection systems, by type of technology (jet, spring and gas), usability (disposable and reusable) and drug volume delivered, [E] prefilled syringes, by type of syringe (glass  and plastic), [F] drug reconstitution systems, by type of device (dual chambered systems and other novel systems), type of container (cartridge and others) and usability (disposable and reusable), [G] implants, by type of material (silicone, titanium, polymers and others), indication, type of implant (biodegradable and non-biodegradable), treatment duration, drug delivered, dosage strength and status of development. As large volume wearable injectors and autoinjectors represent the most novel and advanced types of devices, we have also provided a comprehensive product competitiveness analysis of these products taking into consideration the supplier power (based on size of employee base) and product specifications.

Chapter 10  presents a comprehensive market forecast analysis, highlighting the future potential of the market till the year 2030. It also includes future sales projections of various subcutaneous biologic drug candidates. The chapter presents a detailed market segmentation on the basis of therapeutic areas (autoimmune disorders, metabolic disorders, blood disorders, bone disorders, oncological disorders, genetic disorders, neurological disorders, respiratory disorders and others) and molecule type (proteins, peptides (recombinant), monoclonal antibodies, other antibody based products, cell / gene therapies and vaccines). In addition to the market forecast for subcutaneous biologic drugs, we have also provided an 8-year forecast of subcutaneous delivery systems, including large volume wearable injectors, autoinjectors, prefilled syringes and drug reconstitution systems. It also includes the forecast of revenues that subcutaneous formulation technology developers are likely to generate through licensing agreements. We have provided a view on the likely upfront payments and milestone payments that will be involved in the deals signed or planned with an aim to develop subcutaneous formulation of biologics.

Chapter 11  provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the subcutaneous products market, under a comprehensive SWOT framework. The chapter also features a schematic Harvey ball analysis to highlight the relative impact of each SWOT parameter on the overall subcutaneous products market.

Chapter 12  is a summary of the overall report. In this chapter, we have provided a list of the key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 13  is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with David Daily (Chief Executive Officer and Co-Founder, DALI Medical Devices), Deborah Bitterfield (Chief Executive Officer & Founder, Lindy Biosciences), Frederic Ors (Chief Executive Officer, Immunovaccine Technologies), Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), Menachem Zucker (Vice President and Chief Scientist, Elcam Medical), Michael Reilly (Chief Executive Officer & Co-Founder, Excelse Bio), Michael Hooven (Chief Executive Officer, Enable Injections), Poonam R Velagaleti (Co-Founder, i-novion), Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) and Graham Reynolds (Vice President & General Manager, Global Biologics, West Pharmaceutical Services), and David Heuzé (Communication Leader, MedinCell).

Chapter 14  is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15  is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. Executive Summary
 
3. Introduction
3.1. Chapter Overview
3.2. Types of Therapeutic Molecules
3.3. Biologically Derived Therapeutics
3.3.1. Types of Products
3.3.2. Routes of Administration and Formulations
3.3.3. Subcutaneous Formulations
3.3.3.1. Method of Subcutaneous Administration
3.3.3.2. Advantages of Subcutaneous Administration
3.3.3.3. Limitations of Subcutaneous Administration
 
4. Subcutaneous Biologics: Current Market Landscape
4.1. Chapter Overview
4.2. Subcutaneous Administration of Biologics
4.3. Subcutaneous Biologics: Approved Drugs
4.3.1. Distribution by Approval Year
4.3.2. Distribution by Molecule Type
4.3.3. Distribution by Formulation Type
4.3.4. Key Players
4.3.5. Distribution by Target Therapeutic Area
4.3.6. Distribution by Dosing Frequency
4.3.7. Distribution by Dosage Forms
 
4.4. Subcutaneous Biologics: Clinical Drugs
4.4.1. Distribution by Phase of Development
4.4.2. Distribution by Molecule Type
4.4.3. Distribution by Target Therapeutic Area
4.4.4. Key Players
 
5. Subcutaneous Biologics: Case Studies of Leading Products
5.1. Chapter Overview
5.2. Subcutaneous Biologics: Leading Drugs by Annual Sales
5.3. Case Studies
5.3.1. HUMIRA® (AbbVie, Eisai)
5.3.1.1. Overview
5. 3.1.2. Development History
5. 3.1.3. Target Indications and Dosage Forms
5. 3.1.4. Historical Sales
 
5.3.2. Enbrel® (Amgen, Pfizer, Takeda Pharmaceutical)
5.3.2.1. Overview
5. 3.2.2. Development History
5. 3.2.3. Target Indications and Dosage Forms
5. 3.2.4. Historical Sales
 
5.3.3. RITUXAN® / MabThera® (Biogen, Roche, Chugai Pharmaceutical)
5.3.3.1. Overview
5. 3.3.2. Development History
5. 3.3.3. Target Indications and Dosage Forms
5. 3.3.4. Historical Sales
5. 3.3.5. ENHANZE™ Technology (Halozyme Therapeutics)
5. 3.3.6. Advantages of Subcutaneous RITUXAN® / MabThera® Over Intravenous RITUXAN® / MabThera®
 
5.3.4. Herceptin® (Roche, Chugai Pharmaceutical)
5.3.4.1. Overview
5. 3.4.2. Development History
5. 3.4.3. Target Indications and Dosage Forms
5. 3.4.4. Historical Sales
5. 3.4.5. ENHANZE™ Technology (Halozyme Therapeutics)
5. 3.4.6. Advantages of Subcutaneous Herceptin® Over Intravenous Herceptin®
5. 3.4.7. Herceptin® - Large Volume Wearable Injector Combination Product
 
5.3.5. Neulasta® (Amgen, Kyowa Hakko Kirin)
5.3.5.1. Overview
5.3.5.2. Development History
5.3.5.3. Target Indications and Dosage Forms
5.3.5.4. Historical Sales
 
6. Subcutaneous Formulation Technologies: Current Market Landscape
6.1. Chapter Overview
6.2. Subcutaneous Formulation Technologies: List of Technology Developers
6.2.1. Distribution by Geographical Location of Technology Developers
6.2.2. Distribution by Founding Year of Technology Developers
6.2.3. Distribution by Employee Size of Technology Developers
6.2.4. Distribution by Application of the Technology (Type of Molecule)
6.2.5. Distribution by Possible Routes of Administration
6.2.6. Distribution by Primary Advantage(s) Provided
 
7. Subcutaneous Formulation Technology Developers: Company Competitiveness Analysis
7.1. Chapter Overview
7.2. Subcutaneous Formulation Technology Developers: Competitive Landscape
7.2.1. Scope and Methodology
7.2.2. Three-Dimensional Analysis Based on Supplier Power, Pipeline Strength and Collaborations
 
7.3. Subcutaneous Technology Developers: Benchmark Analysis
7.3.1. Scope and Methodology
7.3.2. North America
7.3.3. Europe
 
8. Subcutaneous Formulation Technology Providers: Company Profiles
8.1. Chapter Overview
8.2. Adocia
8.2.1. Company Overview
8.2.2. BioChaperone® Technology
8.2.3. Product Portfolio
8.2.4. Financial Performance
8.2.5. Recent Developments
8.2.6. Future Outlook
 
8.3. Ajinomoto Althea
8.3.1. Company Overview
8.3.2. Crystalomics® Formulation Technology
8.3.3. Product Portfolio
8.3.4. Financial Performance
8.3.5. Recent Developments
8.3.6. Future Outlook
 
8.4. Arecor
8.4.1. Company Overview
8.4.2. Arestat™ Technology
8.4.3. Product Portfolio
8.4.4. Recent Developments
8.4.5. Future Outlook
 
8.5. Ascendis Pharma
8.5.1. Company Overview
8.5.2. TransCon Technology
8.5.3. Product Portfolio
8.5.4. Financial Performance
8.5.5. Recent Developments
8.5.6. Future Outlook
 
8.6. Avadel Pharmaceuticals
8.6.1. Company Overview
8.6.2. Medusa™ Technology
8.6.3. Product Portfolio
8.6.4. Financial Performance
8.6.5. Recent Developments
8.6.6. Future Outlook
 
8.7. Camurus
8.7.1. Company Overview
8.7.2. FluidCrystal® Injection Depot Technology
8.7.3. Product Portfolio
8.7.4. Financial Performance
8.7.5. Recent Developments
8.7.6. Future Outlook
 
8.8. Halozyme Therapeutics
8.8.1. Company Overview
8.8.2. ENHANZE® Technology
8.8.3. Product Portfolio
8.8.4. Financial Performance
8.8.5. Recent Developments
8.8.6. Future Outlook
 
8.9. MedinCell
8.9.1. Company Overview
8.9.2. BEPO® Technology
8.9.3. Product Portfolio
8.9.4. Recent Developments
8.9.5. Future Outlook
 
8.10. Xeris Pharmaceuticals
8.10.1. Company Overview
8.10.2. Technology Platforms
8.10.2.1. XeriJect™ Technology
8.10.2.2. XeriSol™ Technology
8.10.3. Product Portfolio
8.10.4. Recent Developments
8.10.5. Future Outlook
 
8.11. Serina Therapeutics
8.11.1. Company Overview
8.11.2. POZ™ Drug Delivery Technology
8.11.3. Product Portfolio
8.11.4. Recent Developments
8.11.5. Future Outlook
 
9. Subcutaneous Drug Delivery Systems: Current Market Landscape
9.1. Chapter Overview
9.2. Subcutaneous Drug Delivery Systems: Types
9.3. Subcutaneous Drug Delivery Systems: Overall Market Landscape
9.3.1. Large Volume Wearable Injectors
9.3.1.1. Overview
9.3.1.2. Current Market Landscape of Devices for Non-insulin Biologics
9.3.1.2.1. Distribution by Company
9.3.1.2.2. Distribution by Stage of Development
9.3.1.2.3. Distribution by Device Category
9.3.1.2.4. Distribution by Type of Dose
9.3.1.2.5. Distribution by Storage Capacity
9.3.1.2.6. Distribution by Usability
9.3.1.2.7. Product Competitiveness Analysis
 
9.3.1.3. Current Market Landscape of Devices for Insulin
9.3.1.3.1. Distribution by Company
9.3.1.3.2. Distribution by Stage of Development
9.3.1.3.3. Distribution by Device Category
9.3.1.3.4. Distribution by Storage Capacity
9.3.1.3.5. Distribution by Usability
9.3.1.3.6. Distribution by Availability of CGM System
 
9.3.2. Autoinjectors
9.3.2.1. Overview
9.3.2.2. Current Market Landscape
9.3.2.2.1. Distribution by Company
9.3.2.2.2. Distribution by Type of Primary Drug Container
9.3.2.2.3. Distribution by Usability
9.3.2.2.4. Distribution by Mechanism of Action
9.3.2.2.5. Distribution by Volume of the Drug Container
9.3.2.2.6. Distribution by Type of Dosage
9.3.2.2.7. Product Competitiveness Analysis
9.3.2.3. Drug Device Combination Products
 
9.3.3. Pen Injectors
9.3.3.1. Overview
9.3.3.2. Current Market Landscape
9.3.3.2.1. Distribution by Company
9.3.3.2.2. Distribution by Usability
9.3.3.2.3. Distribution by Volume of the Drug Container
9.3.3.2.4. Distribution by Type of Dosage
9.3.3.3. Drug Device Combination Products
 
9.3.4. Needle Free Injection Systems
9.3.4.1. Overview
9.3.4.2. Current Market Landscape
9.3.4.2.1. Distribution by Company
9.3.4.2.2. Distribution by Usability
9.3.4.2.3. Distribution by Type of Technology
 
9.3.5. Drug Reconstitution Delivery Systems
9.3.5.1. Overview
9.3.5.2. Current Market Landscape
9.3.5.2.1. Distribution by Company
9.3.5.2.2. Distribution by Usability
9.3.5.2.3. Distribution by Device Category
 
9.3.6. Prefilled Syringes
9.3.6.1. Overview
9.3.6.2. Current Market Landscape
9.3.6.3. Glass Prefilled Syringes
9.3.6.4. Plastic Prefilled Syringes
9.3.6.5. Drug Device Combination Products
 
9.3.7. Implants
9.3.7.1. Overview
9.3.7.2. Current Market Landscape
9.3.7.2.1. Distribution by Company
9.3.7.2.2. Distribution by Stage of Development
9.3.7.2.3. Distribution by Type of Delivery System
9.3.7.2.4. Distribution by Type of Material
9.3.7.2.5. Distribution by Treatment Duration
9.3.7.2.6. Distribution by Indication
 
10. Market Forecast and Opportunity Analysis
10.1. Chapter Overview
10.2. Subcutaneous Biologics Market
10.2.1. Forecast Methodology
10.2.2. Overall Market
10.2.3. Distribution by Phase of Development
10.2.4. Distribution by Molecule Type
10.2.5. Distribution by Therapeutic Area
 
10.3. Subcutaneous Drug Delivery Systems Market
10.3.1. Large Volume Wearable Injectors Market
10.3.2. Forecast Methodology
10.3.3. Overall Market
10.3.4. Autoinjectors Market
10.3.5. Forecast Methodology
10.3.6. Overall Market
10.3.7. Prefilled Syringes Market
10.3.8. Forecast Methodology
10.3.9. Overall Market
10.3.10. Novel Drug Reconstitution Systems Market
10.3.11. Forecast Methodology
10.3.12. Overall Market
 
10.4. Subcutaneous Formulation Technology Licensing Revenues
 
11. SWOT Analysis
11.1. Chapter Overview
11.2. Comparison of SWOT Factors
11.2.1. Strengths
11.2.2. Weaknesses
11.2.3. Opportunities
11.2.4. Threats
 
12. Conclusion
12.1. Rising Trend of Self-Administration and the Need to Improve Therapy Adherence have Increased the Popularity of Subcutaneous Formulations of Biologics
12.2. The Pipeline Features Contributions of Several Pharma Giants; Presently, Monoclonal Antibodies are the Most Popular Type of Molecules Being Evaluated Across Various Therapeutic Areas
12.3. In Order to Overcome the Challenges Related to Formulating Biologics for Subcutaneous Delivery, Multiple Companies have Developed Innovative Technology Platforms
12.4. Large Volume Wearable Injectors and Autoinjectors are Amongst the Novel Device Types used for Subcutaneous Drug Administration
12.5. Despite Various Limitations, the Field Offers Significant Opportunities to a Variety of Stakeholders
12.6. Driven by the Demand for Self-Injectable Medications and Ongoing Innovation, the Market for Subcutaneous Biologics, Delivery Devices and Technologies is Anticipated to Witness Significant Growth in the Long Term
 
13. Executive Insights
13.1. Chapter Overview
 
13.2. DALI Medical Devices
13.2.1. Company Snapshot
13.2.2. Interview Transcript: David Daily, Chief Executive Officer & Co-Founder
 
13.3. Lindy Biosciences
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Deborah Bitterfield, Chief Executive Officer & Founder
 
13.4. Immunovaccine Technologies
13.4.1. Company Snapshot
13.4.2. Interview Transcript: Frederic Ors, Chief Executive Officer
 
13.5. Oval Medical Technologies
13.5.1. Company Snapshot
13.5.2. Interview Transcript: Matthew Young, Founder & Chief Technology Officer
 
13.6. Elcam Medical
13.6.1. Company Snapshot
13.6.2. Interview Transcript: Menachem Zucker, Vice President & Chief Scientist
 
13.7. Excelse Bio
13.7.1. Company Snapshot
13.7.2. Interview Transcript: Michael Reilly, Chief Executive Officer & Co-Founder
 
13.8. Enable Injections
13.8.1. Company Snapshot
13.8.2. Interview Transcript: Michael Hooven, Chief Executive Officer
 
13.9. i-novion
13.9.1. Company Snapshot
13.9.2. Interview Transcript: Poonam R Velagaleti, Co-Founder
 
13.10. West Pharmaceutical Services
13.10.1. Company Snapshot
13.10.2. Interview Transcript: Tiffany H Burke, Director, Global Communications and Graham Reynolds, Vice President & General Manager, Global Biologics
13.11. MedinCell
13.11.1. Company Snapshot
13.11.2. Interview Transcript: David Heuzé, Communication Leader
 
14. Appendix 1: List of Companies and Organizations
 
15. Appendix 2: List of Companies and Organizations

List of Figures

Figure 3.1 Types of Biologically Derived Therapeutics
Figure 3.2 Subcutaneous Drug Delivery: Possible Routes of Administration for Large-Dose Biologics
Figure 3.3 Landscape of Large Volume Subcutaneous Drug Delivery Devices
Figure 3.4 Steps Involved in Subcutaneous Drug Delivery
Figure 4.1 Approved Subcutaneous Biologics: Distribution by Approval Year
Figure 4.2 Approved Subcutaneous Biologics: Distribution by Molecule Type
Figure 4.3 Approved Subcutaneous Biologics: Distribution by Formulation Type
Figure 4.4 Approved Subcutaneous Biologics: Key Players
Figure 4.5 Approved Subcutaneous Biologics: Distribution by Target Therapeutic Area
Figure 4.6 Approved Subcutaneous Biologics: Distribution by Dosing Frequency
Figure 4.7 Approved Subcutaneous Biologics: Distribution by Dosage Forms
Figure 4.8 Clinical Subcutaneous Biologics: Distribution by Phase of Development
Figure 4.9 Clinical Subcutaneous Biologics: Distribution by Molecule Type
Figure 4.10 Clinical Subcutaneous Biologics: Distribution by Target Therapeutic Area
Figure 4.11 Clinical Subcutaneous Biologics: Key Players
Figure 5.1 Subcutaneous Biologics: Leading Drugs Based on Annual Sales, 2017 (USD Billion)
Figure 5.2 HUMIRA®: Approval Timeline (US, EU and Japan)
Figure 5.3 HUMIRA®: Approval Timeline for Various Dosage Forms (US and EU)
Figure 5.4 HUMIRA®: Annual Sales, 2003-Q1 2018 (USD Billion)
Figure 5.5 Enbrel®: Approval Timeline for Various Dosage Forms (US and EU)
Figure 5.6 Enbrel®: Annual Sales in the US and Canada, 2002-Q1 2018 (USD Billion)
Figure 5.7 Enbrel®: Annual Sales Outside US and Canada, 2010-Q1 2018 (USD Billion)
Figure 5.8 RITUXAN® / MabThera®: Annual Sales, 1999-2017 (CHF Billion)
Figure 5.9 Herceptin®: Annual Sales, 1999 –2017 (CHF Billion)
Figure 5.10 Neulasta®: Annual Sales, 2005 – Q1 2018 (USD Billion)
Figure 6.1 High Concentration Protein Formulations: Advantages
Figure 6.2 High Concentration Protein Formulations: Associated Challenges
Figure 6.3 Subcutaneous Formulation Technologies: Distribution by Geographical Location of Technology Developers
Figure 6.4 Subcutaneous Formulation Technologies: Distribution by Founding Year of Technology Developers
Figure 6.5 Subcutaneous Formulation Technologies: Distribution by Employee Size of Technology Developers
Figure 6.6 Subcutaneous Formulation Technologies: Distribution by Application of the Technology (Type of Molecule)
Figure 6.7 Subcutaneous Formulation Technologies: Distribution by Possible Routes of Administration
Figure 6.8 Subcutaneous Formulation Technologies: Distribution by Primary Advantage(s) Provided
Figure 6.9 Subcutaneous Formulation Technologies: Logo Landscape by Primary Advantage(s) Provided and Company Size
Figure 7.1 Subcutaneous Formulation Technology Developers: Three-Dimensional Analysis by Supplier Power, Pipeline Strength and Collaborations
Figure 7.2 Subcutaneous Formulation Technology Developers: Benchmark Analysis (North America)
Figure 7.3 Subcutaneous Technology Developers: Benchmark Analysis (Europe)
Figure 8.1 Adocia: Annual Revenues, 2014–2017 (EUR Million)
Figure 8.2 Ajinomoto Althea: Service Portfolio
Figure 8.3 Ajinomoto Althea: Crystalomics® Technology (Process Steps)
Figure 8.4 Ajinomoto: Annual Revenues, FY1213 – FY1718 (JPY Billion)
Figure 8.5 Arecor: Advantages of Arestat™ Technology
Figure 8.6 Ascendis Pharma: Annual Revenues, 2012-Q1 2018 (EUR Million)
Figure 8.7 Avadel Pharmaceuticals: Medusa™ Technology (Process Steps)
Figure 8.8 Avadel Pharmaceuticals: Annual Revenues, 2013 – Q1 2018 (USD Million)
Figure 8.9 Camurus: FluidCrystal® Technology (Process Steps)
Figure 8.10 Camurus: Annual Revenues, 2013-Q1 2018 (SEK Million)
Figure 8.11 Halozyme Therapeutics: Annual Revenues, 2009 – Q1 2018 (USD Million)
Figure 8.12 MedinCell: BEPO® Technology (Process Steps)
Figure 8.13 Xeris Pharmaceuticals: XeriJect™ Technology (Process Steps)
Figure 8.14 Xeris Pharmaceuticals: XeriSol™ Technology (Process Steps)
Figure 9.1 Subcutaneous Drug Delivery Systems: Types
Figure 9.2 Subcutaneous Drug Delivery Systems: Overall Market Landscape by Number of Involved Players
Figure 9.3 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Company
Figure 9.4 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Stage of Development
Figure 9.5 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Device Category
Figure 9.6 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Type of Dose
Figure 9.7 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Storage Capacity
Figure 9.8 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Usability
Figure 9.9 Large Volume Wearable Injectors for Non-Insulin Biologics: Product Competitiveness Analysis
Figure 9.10 Large Volume Wearable Injectors for Insulin: Distribution by Company
Figure 9.11 Large Volume Wearable Injectors for Insulin: Distribution by Stage of Development
Figure 9.12 Large Volume Wearable Injectors for Insulin: Distribution by Device Category
Figure 9.13 Large Volume Wearable Injectors for Insulin: Distribution by Storage Capacity
Figure 9.14 Large Volume Wearable Injectors for Insulin: Distribution by Usability
Figure 9.15 Large Volume Wearable Injectors for Insulin: Distribution by Availability of CGM System
Figure 9.16 Autoinjectors: Distribution by Company
Figure 9.17 Autoinjectors: Distribution by Primary Drug Container
Figure 9.18 Autoinjectors: Distribution by Usability
Figure 9.19 Autoinjectors: Distribution by Mechanism of Action
Figure 9.20 Autoinjectors: Distribution by Volume of the Drug Container
Figure 9.21 Autoinjectors: Distribution by Dosage Type
Figure 9.22 Autoinjectors: Product Competitiveness Analysis
Figure 9.23 Pen Injectors: Distribution by Company
Figure 9.24 Pen Injectors: Distribution by Usability
Figure 9.25 Pen Injectors: Distribution by Volume of the Drug Container
Figure 9.26 Pen Injectors: Distribution by Dosage Type
Figure 9.27 Needle Free Injection Systems: Distribution by Company
Figure 9.28 Needle Free Injection Systems: Distribution by Usability
Figure 9.29 Needle Free Injection Systems: Distribution by Type of Technology
Figure 9.30 Novel Drug Reconstitution Systems: Distribution by Company
Figure 9.31 Novel Drug Reconstitution Systems: Distribution by Usability
Figure 9.32 Novel Drug Reconstitution Systems: Distribution by Device Category
Figure 9.33 Prefilled Syringes: Distribution by Manufacturers and Type of Syringe
Figure 9.34 Implants: Distribution by Company
Figure 9.35 Implants: Distribution by Stage of Development
Figure 9.36 Implants: Distribution by Type of Delivery System
Figure 9.37 Implants: Distribution by Type of Material
Figure 9.38 Implants: Distribution by Treatment Duration
Figure 9.39 Implants: Distribution by Indication
Figure 10.1 Overall Subcutaneous Biologics Market, 2018-2030 (USD Billion)
Figure 10.2 Subcutaneous Biologics Market: Distribution by Phase of Development, 2018-2030 (USD Billion)
Figure 10.3 Subcutaneous Biologics Market: Distribution by Molecule Type, 2020, 2025, 2030 (USD Billion)
Figure 10.4 Subcutaneous Biologics Market: Market Attractive Analysis by Molecule Type, 2018-2030 (USD Billion)
Figure 10.5 Subcutaneous Biologics Market: Distribution by Therapeutic Area, 2020, 2025, 2030 (USD Billion)
Figure 10.6 Large Volume Wearable Injectors Market for Non-Insulin Biologics, 2018-2025 (USD Million)
Figure 10.7 Large Volume Wearable Injectors Market for Non-Insulin Biologics, 2018-2025 (Units, Million)
Figure 10.8 Large Volume Wearable Injectors Market for Insulin, 2018-2025 (USD Million)
Figure 10.9 Large Volume Wearable Injectors Market for Insulin, 2018-2025 (Units, Million)
Figure 10.10 Autoinjectors Market, 2018-2025 (USD Million)
Figure 10.11 Autoinjectors Market, 2018-2025 (Units, Million)
Figure 10.12 Prefilled Syringes Price Curve, (USD per unit)
Figure 10.13 Prefilled Syringes Market, 2018-2025 (USD Million)
Figure 10.14 Prefilled Syringes Market, 2018-2025 (Units, Million)
Figure 10.15 Novel Drug Reconstitution Systems Market, 2018-2025 (USD Million)
Figure 10.16 Subcutaneous Formulation Technologies Market: Distribution by Type of Payment, 2018-2030 (USD Million)
Figure 11.1 SWOT Analysis: Harvey Ball Analysis
Figure 11.2 Number of Biologics Approved by the FDA, 2011-2017
Figure 12.1 Subcutaneous Biologics Market: Distribution by Type of Molecule, 2018, 2025, 2030 (USD Billion)

List of Tables

Table 3.1 Comparison of Characteristics of Small Molecules and Biologics
Table 3.2 Parenteral Routes of Administration
Table 3.3 Physical and Chemical Instabilities Associated with Parenteral Drug Formulations
Table 3.4 Parenteral Formulations: Key Excipient Types
Table 4.1 List of Approved Subcutaneous Biologics
Table 4.2 Approved Subcutaneous Biologics: Details on Targeted Indication and Therapeutic Area
Table 4.3 Approved Subcutaneous Biologics: Details on Dosage Frequency and Dosage Forms
Table 4.4 Approved Subcutaneous Biologics: Distribution by Dosage Form and Therapeutic Area
Table 4.5 List of Clinical Subcutaneous Biologics
Table 5.1 HUMIRA®: Approved Indications and Dosage Regimen
Table 5.2 Enbrel®: Approved Indications and Dosage Regimen
Table 5.3 RITUXAN® / MabThera®: Approved Indications and Therapy Type
Table 5.4 Comparison of Subcutaneous and Intravenous Formulations of RITUXAN® / MabThera®
Table 5.5 Herceptin®: Approved Indications and Therapy Type
Table 5.6 Comparison of Subcutaneous and Intravenous Formulations of Herceptin®
Table 5.7 Cost Comparison for Patients Treated with Intravenous Herceptin® or Subcutaneous Herceptin®
Table 5.8 Subcutaneous Herceptin® in Single-Use Injection Device: Clinical Trials
Table 6.1 Subcutaneous Formulation Technologies: List of Technology Developers
Table 6.2 Subcutaneous Formulation Technologies: Details on Applications by Molecule Type
Table 6.3 Subcutaneous Formulation Technologies: Details on Possible Routes of Administration
Table 6.4 Subcutaneous Formulations Technologies: Details on Mechanism of Action and Primary Advantage(s) Provided
Table 7.1 Subcutaneous Formulation Technology Developers: Relative Scoring by Supplier Power, Pipeline Strength and Collaborations
Table 8.1 Adocia: Product Portfolio
Table 8.2 Adocia: Collaborations
Table 8.3 Adocia: Funding
Table 8.4 Ajinomoto Althea: Collaborations
Table 8.5 Ajinomoto Althea: Funding
Table 8.6 Arecor: Product Portfolio
Table 8.7 Arecor: Collaborations
Table 8.8 Arecor: Funding
Table 8.9 Ascendis Pharma: Product Portfolio
Table 8.10 Ascendis Pharma: Collaborations
Table 8.11 Ascendis Pharma: Funding
Table 8.12 Avadel Pharmaceuticals: Product Portfolio
Table 8.13 Avadel Pharmaceuticals: Collaborations
Table 8.14 Avadel Pharmaceuticals: Funding
Table 8.15 Camurus: Product Portfolio
Table 8.16 Camurus: Collaborations
Table 8.17 Camurus: Funding
Table 8.18 Halozyme Therapeutics: Product Portfolio
Table 8.19 Halozyme Therapeutics: Collaborations
Table 8.20 Halozyme Therapeutics: Funding
Table 8.21 MedinCell: Product Portfolio
Table 8.22 MedinCell: Collaborations
Table 8.23 MedinCell: Funding
Table 8.24 Xeris Pharmaceuticals: Product Portfolio
Table 8.25 Xeris Pharmaceuticals: Collaborations
Table 8.26 Xeris Pharmaceuticals: Funding
Table 8.27 Serina Therapeutics: Product Portfolio
Table 8.28 Serina Therapeutics: Collaborations
Table 8.29 Serina Therapeutics: Funding
Table 9.1 Subcutaneous Drug Delivery Systems: Key Companies
Table 9.2 Large Volume Wearable Injectors: Development Landscape for Non-Insulin Biologics
Table 9.3 Large Volume Wearable Injectors: Development Landscape for Insulin
Table 9.4 Autoinjectors: Development Landscape, 
Table 9.5 List of Drug and Autoinjector Combination Products
Table 9.6 Pen Injectors: Development Landscape
Table 9.7 List of Drug and Pen Injector Combination Products
Table 9.8 Needle Free Injection Systems: Development Landscape
Table 9.9 Novel Drug Reconstitution Systems: Development Landscape
Table 9.10 Prefilled Syringe Systems: List of Manufacturers
Table 9.11 Glass Prefilled Syringes Available in the Market
Table 9.12 Plastic Prefilled Syringes Available in the Market
Table 9.13 Drugs Approved in Prefilled Syringes, 2013-2016, 
Table 9.14 Other Drugs Sold in Prefilled Syringes
Table 9.15 Implants: Development Landscape
Table 10.1 Large Volume Wearable Injectors for Non-Insulin Biologics (Approved / Under Development)
Table 10.2 Prefilled Syringes Price Estimate (USD per unit)
Table 14.1 Approved Subcutaneous Biologics: Distribution by Approval Year
Table 14.2 Approved Subcutaneous Biologics: Distribution by Molecule Type
Table 14.3 Approved Subcutaneous Biologics: Distribution by Formulation Type
Table 14.4 Approved Subcutaneous Biologics: Key Players
Table 14.5 Approved Subcutaneous Biologics: Distribution by Target Therapeutic Area
Table 14.6 Approved Subcutaneous Biologics: Distribution by Dosing Frequency
Table 14.7 Approved Subcutaneous Biologics: Distribution by Dosage Forms
Table 14.8 Clinical Subcutaneous Biologics: Distribution by Phase of Development
Table 14.9 Clinical Subcutaneous Biologics: Distribution by Molecule Type
Table 14.10 Clinical Subcutaneous Biologics: Distribution by Target Therapeutic Area
Table 14.11 Clinical Subcutaneous Biologics: Key Players
Table 14.12 Subcutaneous Biologics: Leading Drugs Based on Annual Sales, 2017 (USD Billion)
Table 14.13 HUMIRA®: Annual Sales, 2003-Q1 2018 (USD Billion)
Table 14.14 Enbrel®: Annual Sales in the US and Canada, 2002-Q1 2018 (USD Billion)
Table 14.15 Enbrel®: Annual Sales Outside US and Canada, 2010-Q1 2018 (USD Billion)
Table 14.16 RITUXAN® / MabThera®: Annual Sales, 1999-2017 (CHF Billion)
Table 14.17 Herceptin®: Annual Sales, 1999 –2017 (CHF Billion)
Table 14.18 Neulasta®: Annual Sales, 2005 – Q1 2018 (USD Billion)
Table 14.19 Subcutaneous Formulation Technologies: Distribution by Geographical Location of Technology Developers
Table 14.20 Subcutaneous Formulation Technologies: Distribution by Founding Year of Technology Developers
Table 14.21 Subcutaneous Formulation Technologies: Distribution by Employee Size of Technology Developers
Table 14.22 Subcutaneous Formulation Technologies: Distribution by Application of the Technology (Type of Molecule)
Table 14.23 Subcutaneous Formulation Technologies: Distribution by Possible Routes of Administration
Table 14.24 Subcutaneous Formulation Technologies: Distribution by Primary Advantage(s) Provided
Table 14.25 Adocia: Annual Revenues, 2014–2017 (EUR Million)
Table 14.26 Ajinomoto: Annual Revenues, FY1213 – FY1718 (JPY Billion)
Table 14.27 Ascendis Pharma: Annual Revenues, 2012-Q1 2018 (EUR Million)
Table 14.28 Avadel Pharmaceuticals: Annual Revenues, 2013 – Q1 2018 (USD Million)
Table 14.29 Camurus: Annual Revenues, 2013-Q1 2018 (SEK Million)
Table 14.30 Halozyme Therapeutics: Annual Revenues, 2009 – Q1 2018 (USD Million)
Table 14.31 Subcutaneous Drug Delivery Systems: Overall Market Landscape by Number of Involved Players
Table 14.32 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Company
Table 14.33 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Stage of Development
Table 14.34 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Device Category
Table 14.35 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Type of Dose
Table 14.36 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Storage Capacity
Table 14.37 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Usability
Table 14.38 Large Volume Wearable Injectors for Insulin: Distribution by Company
Table 14.39 Large Volume Wearable Injectors for Insulin: Distribution by Stage of Development
Table 14.40 Large Volume Wearable Injectors for Insulin: Distribution by Device Category
Table 14.41 Large Volume Wearable Injectors for Insulin: Distribution by Storage Capacity
Table 14.42 Large Volume Wearable Injectors for Insulin: Distribution by Usability
Table 14.43 Large Volume Wearable Injectors for Insulin: Distribution by Availability of CGM System
Table 14.44 Autoinjectors: Distribution by Company
Table 14.45 Autoinjectors: Distribution by Primary Drug Container
Table 14.46 Autoinjectors: Distribution by Usability
Table 14.47 Autoinjectors: Distribution by Mechanism of Action
Table 14.48 Autoinjectors: Distribution by Volume of the Drug Container
Table 14.49 Autoinjectors: Distribution by Dosage Type
Table 14.50 Pen Injectors: Distribution by Company
Table 14.51 Pen Injectors: Distribution by Usability
Table 14.52 Pen Injectors: Distribution by Volume of the Drug Container
Table 14.53 Pen Injectors: Distribution by Dosage Type
Table 14.54 Needle Free Injection Systems: Distribution by Company
Table 14.55 Needle Free Injection Systems: Distribution by Usability
Table 14.56 Needle Free Injection Systems: Distribution by Type of Technology
Table 14.57 Novel Drug Reconstitution Systems: Distribution by Company
Table 14.58 Novel Drug Reconstitution Systems: Distribution by Usability
Table 14.59 Novel Drug Reconstitution Systems: Distribution by Device Category
Table 14.60 Implants: Distribution by Company
Table 14.61 Implants: Distribution by Stage of Development
Table 14.62 Implants: Distribution by Type of Delivery System
Table 14.63 Implants: Distribution by Type of Material
Table 14.64 Implants: Distribution by Treatment Duration
Table 14.65 Implants: Distribution by Indication
Table 14.66 Overall Subcutaneous Biologics Market, 2018-2030 (USD Billion)
Table 14.67 Subcutaneous Biologics Market: Distribution by Phase of Development, 2018-2030 (USD Billion)
Table 14.68 Subcutaneous Biologics Market: Distribution by Molecule Type, 2020, 2025, 2030 (USD Billion)
Table 14.69 Subcutaneous Biologics Market: Distribution by Therapeutic Area, 2018, 2025, 2030 (USD Billion)
Table 14.70 Large Volume Wearable Injectors Market for Non-Insulin Biologics, 2018-2025 (USD Million)
Table 14.71 Large Volume Wearable Injectors Market for Non-Insulin Biologics, 2018-2025 (Units, Million)
Table 14.72 Large Volume Wearable Injectors Market for Insulin, 2018-2025 (USD Million)
Table 14.73 Large Volume Wearable Injectors Market for Insulin, 2018-2025 (Units, Million)
Table 14.74 Autoinjectors Market, 2018-2025 (USD Million)
Table 14.75 Autoinjectors Market, 2018-2025 (Units, Million)
Table 14.76 Prefilled Syringes Market, 2018-2025 (USD Million)
Table 14.77 Prefilled Syringes Market, 2018-2025 (Units, Million)
Table 14.78 Novel Drug Reconstitution Systems Market, 2018-2025 (USD Million)
Table 14.79 Subcutaneous Formulation Technologies Market: Distribution by Type of Payment, 2018 – 2030 (USD Million)
Table 14.80 Number of Biologics Approved by the FDA, 2011-2017
Table 14.81 Subcutaneous Biologics Market: Distribution by Type of Molecule, 2018, 2025, 2030 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report. 

  1. 3D Medicines
  2. AB2 Bio
  3. Abbott Laboratories
  4. AbbVie
  5. Ablynx
  6. AC Immune
  7. Acceleron Pharma
  8. Accord Healthcare
  9. Acer Therapeutics
  10. ACG Management
  11. Adisave
  12. Adocia
  13. Affibody
  14. Aguettant
  15. Aijex Pharma International
  16. Ajinomoto Althea
  17. AKRA DERMOJET
  18. Alder BioPharmaceuticals
  19. Alexion Pharmaceuticals
  20. Alkermes
  21. Allergan
  22. Alopexx Oncology
  23. Alphamab
  24. Altor BioScience
  25. Altus Pharmaceuticals
  26. Alvogen
  27. ALZA  
  28. AMAG Pharmaceuticals
  29. Amedra Pharmaceuticals 
  30. Amgen
  31. Amgen Astellas BioPharma
  32. AnaptysBio
  33. ANDROSYSTEMS
  34. Antares Pharma
  35. Anterogen
  36. Anthera Pharmaceuticals
  37. Aphios
  38. Apobiologix 
  39. Apotex
  40. Araclon Biotech
  41. Arecor
  42. argenx
  43. ARMO BioSciences
  44. Arsia Therapeutics
  45. ARTE 
  46. Asahi Kasei
  47. Ascendis Pharma 
  48. Aspen Pharmacare
  49. Astellas Pharma
  50. AstraZeneca
  51. Athyrium Capital Management
  52. Atridia
  53. Avadel Pharmaceuticals
  54. Avid Bioservices
  55. Avillion
  56. Axxia Pharmaceuticals
  57. BASF 
  58. Bavarian Nordic
  59. Baxalta
  60. Bay City Capital
  61. Bayer
  62. Becton Dickinson
  63. Beijing Dongfang Biotech
  64. Beijing Northland Biotech
  65. Bespak
  66. Bill & Melinda Gates Foundation
  67. Bioam Gestion
  68. BioAtla
  69. BIOCAD
  70. Biocorp
  71. Biogen
  72. Bioject Medical Technologies
  73. BioMarin
  74. Biomay
  75. Bird Rock Bio
  76. Boehringer Ingelheim
  77. Boston Pharmaceuticals
  78. Braeburn Pharmaceuticals
  79. Bristol Myers Squibb
  80. Britannia Pharmaceuticals
  81. Broadfin Capital
  82. Cadila Pharmaceuticals
  83. Cam Med
  84. Cambridge Antibody Technology
  85. Cambridge Consultants
  86. Camurus
  87. Carbion
  88. Catalyst Biosciences
  89. CDC Enterprises
  90. Celgene
  91. Celldex Therapeutics
  92. Cellnovo
  93. Central Texas Angel Network 
  94. CeQur
  95. Chugai Pharmaceutical
  96. CinnaGen
  97. Cleveland BioLabs
  98. CM-CIC Innovation
  99. College Diabetes Network
  100. Companion Medical
  101. Complex Biosystems
  102. Copernicus
  103. Corbion
  104. Corvidia Therapeutics
  105. Crescendo Pharmaceuticals
  106. Crossject
  107. CSL Behring
  108. CSPC Pharmaceutical 
  109. CuraVac
  110. CytoDyn
  111. Cytori Therapeutics
  112. Daiichi Sankyo
  113. Daikyo Seiko
  114. DALI Medical Devices
  115. Debiotech
  116. Deerfield Management
  117. Delpor
  118. Dermira
  119. DiaMedica Therapeutics
  120. Diasome Pharmaceuticals
  121. Digna Biotech
  122. Dongbao
  123. Dr. Reddy's Laboratories
  124. DSM Venturing
  125. Dyax
  126. Eagle Pharmaceuticals
  127. Eddingpharm
  128. Eiger BioPharmaceuticals
  129. Eisai
  130. Elcam Medical
  131. Elektrofi
  132. Eli Lilly
  133. EMD Serono
  134. Emergent BioSolutions
  135. Emperra
  136. Enable Injections
  137. Endo Pharmaceuticals
  138. Epilepsy Foundation
  139. Etubics 
  140. European Pharma Group 
  141. Excelse Bio
  142. EyeTech
  143. Ferring Pharmaceuticals
  144. Finox Biotech
  145. Flamel Technologies
  146. Flowonix Medical
  147. FluGen
  148. Fresenius Kabi
  149. FUJIFILM Diosynth Biotechnologies
  150. Future Injection Technologies
  151. Fuze
  152. GALVmed
  153. GC Pharma
  154. Genentech
  155. Generon (Shanghai) 
  156. Genexine
  157. Genmab
  158. Genor Biopharma
  159. GEROPHARM
  160. Gerresheimer
  161. Gilde Healthcare 
  162. Gilead Sciences
  163. GlaxoSmithKline
  164. Globe Medical Tech
  165. GlobeImmune
  166. Grifols
  167. HAL Allergy Group
  168. Halozyme Therapeutics
  169. Hanall Biopharma
  170. Hanmi Pharmaceutical
  171. Harbour BioMed
  172. Haselmeier
  173. Hercules Capital
  174. Heron Therapeutics
  175. Hospira
  176. Human Genome Sciences
  177. IDINVEST Partners
  178. ILTOO Pharma
  179. Il-Yang Pharmaceutical
  180. Immunex
  181. Immunomedics
  182. ImmunoVaccine Technologies
  183. Immutep
  184. Impax Laboratories
  185. Incepta Pharmaceuticals
  186. Inmunotek
  187. Innovate UK
  188. Inolife Sciences Inc
  189. Inovio Pharmaceuticals
  190. i-novion
  191. Insense
  192. Insulet 
  193. Insuline Medical
  194. Intarcia Therapeutics
  195. Integrity Bio
  196. Intrexon
  197. Ipsen
  198. ISU ABXIS
  199. Izana Bioscience
  200. JO Pharma 
  201. Janssen Biotech
  202. Janus Capital Group
  203. JCR Pharmaceuticals
  204. Jiangsu Delfu Medical Device
  205. Jiangsu Wan Hai Medical Instruments
  206. Jiangsu Hengrui Medicine
  207. Johnson & Johnson
  208. Juvenile Diabetes Research Foundation
  209. Kaléo 
  210. Kangstem Biotech
  211. Kastle Therapeutics
  212. Kedrion Biopharma
  213. King Pharmaceuticals
  214. Kingsbury Capital Partners
  215. Kitasato Daiichi Sankyo Vaccine
  216. Knight Therapeutics
  217. Kolltan Pharmaceuticals
  218. Kyowa Hakko Kirin
  219. Lapeyronie Hospital
  220. Lenis Medical
  221. LEO Pharma
  222. Lindy Biosciences
  223. Lineage Therapeutics
  224. Lundbeck
  225. Lupin
  226. Luye Pharma 
  227. Maruho
  228. Maruishi Pharmaceutical
  229. Massachusetts Institute of Technology
  230. McNair Group
  231. Medac Pharma
  232. Medical International Technologies (MIT Canada)
  233. Medicom Innovation Partner
  234. MedImmune
  235. MedinCell
  236. Medipacs
  237. MedPro 
  238. Medtronic
  239. Medtrum
  240. Merck
  241. Merck Serono
  242. Merieux Développement
  243. MGlas 
  244. MicroVAX
  245. Mika Medical
  246. Miracle Medical
  247. Mitsubishi Tanabe Pharma
  248. MJ Biopharm
  249. Momenta Pharmaceuticals
  250. MorphoSys
  251. Mylan
  252. Nano Precision Medical
  253. National Institute of Diabetes and Digestive and Kidney Diseases 
  254. National Institute of Neurological Disorders and Stroke
  255. National Medical Products
  256. Nektar Therapeutics
  257. Nemera
  258. Neumedicines
  259. Neurimmune
  260. NeuroDerm
  261. NGM Bio
  262. Nippon Organon
  263. Nipro Medical 
  264. Novartis
  265. Novimmune
  266. Novo Nordisk
  267. NPS Pharmaceuticals
  268. Numab
  269. Nuova Ompi
  270. Omeros 
  271. Oncolix 
  272. OPKO Health
  273. OrbiMed
  274. Orphan Technologies
  275. Otsuka Pharmaceutical
  276. Oval Medical Technologies
  277. Owen Mumford
  278. Oxford Finance 
  279. PA Consulting 
  280. Palmetto Partners
  281. Penjet 
  282. Pfizer
  283. PharmaJet
  284. Pharmakon Advisors
  285. PharmaSens
  286. Pharmstandard
  287. PhaseBio Pharmaceuticals
  288. Philogen
  289. Phoundry Pharmaceuticals
  290. Plas-Tech Engineering
  291. Polfa Tarchomin
  292. Population Council
  293. Portal Instruments
  294. ProJect Pharmaceutics
  295. Promius Pharma
  296. Provenance Biopharmaceuticals
  297. Qu Biologics
  298. RA Capital Management
  299. Receptos
  300. Redmile Group
  301. ReForm Biologics
  302. Regeneron Pharmaceuticals
  303. REMD Biotherapeutics
  304. Revolutions Medical
  305. Rhône-Poulenc Rorer
  306. RMS Medical Products
  307. Roche
  308. Rock Springs Capital
  309. Roselabs Bioscience
  310. ROXALL Medizin
  311. R-PHARM
  312. Sabby Management
  313. Salix Pharmaceuticals
  314. Samsung Bioepis
  315. Sandoz
  316. Sanofi
  317. Schering-Plough 
  318. SCHOTT
  319. Sensile Medical
  320. Seqirus
  321. Serina Therapeutics
  322. Serum Institute of India
  323. Shandong Pharmaceutical Glass
  324. Shandong Zibo Minkang Pharmaceutical Packing
  325. Shanghai Dahua Pharmaceutical
  326. Shanghai Umitai Medical Technology 
  327. Shin Yan Sheno Precision Industrial
  328. Shire
  329. SHL Group
  330. SiO2 Medical Products
  331. Silicon Valley Bank
  332. SK Chemicals
  333. Société Générale Asset Management
  334. Sofinnova Partners
  335. SOOIL Development
  336. SOTIO
  337. Spectrum Pharmaceuticals
  338. Square Pharmaceuticals
  339. STADA Arzneimittel
  340. SteadyMed Therapeutics
  341. Subcuject
  342. Sumitomo Dainippon Pharma
  343. Sun Pharmaceutical Industries
  344. Swedish Orphan Biovitrum
  345. Synthon Hispania
  346. Taisei Kako
  347. Taisho Pharmaceutical
  348. Takeda Pharmaceutical
  349. Talecris Biotherapeutics
  350. Tandem Diabetes Care
  351. Telegraph Hill Partners
  352. TerSera Therapeutics
  353. Terumo 
  354. Teva Pharmaceutical 
  355. Texas Diabetes Institute
  356. Texas Emerging Technologies Fund
  357. The National Institute for Health and Care Excellence
  358. Theralpha
  359. Tianjin SinoBiotech
  360. Titan Pharmaceuticals
  361. Torii Pharmaceutical
  362. Touche Medical
  363. Transgene
  364. TREOS Bio
  365. Tyfill Pharmapack
  366. U.S. Medical Instruments
  367. UCB Pharma
  368. Ultragenyx Pharmaceutical
  369. Uman Pharma
  370. Uni-Bio Science Group
  371. Unilever
  372. Unilife 
  373. Union Medico
  374. United BioPharma
  375. United Therapeutics
  376. University of Colorado
  377. University of Texas Health Science Center
  378. US WorldMeds
  379. Valeant Pharmaceuticals 
  380. Valeritas
  381. Venrock
  382. Ventana Medical Systems 
  383. Vetter Pharma
  384. ViaCyte
  385. ViCentra
  386. Viela Bio 
  387. ViroMed
  388. ViroPharma
  389. Vitaeris
  390. Vivo Capital
  391. West Pharmaceutical Services
  392. Wild Basin Investments
  393. Wyss Institute 
  394. XBiotech
  395. XEME Biopharma
  396. Xencor
  397. Xeris Pharmaceuticals
  398. YangZhong Wealth Metal
  399. Youlyy Industrial
  400. Ypsomed 
  401. Zensun
  402. Zogenix
  403. Zweite TechnoStart Ventures Fonds
     

PRICING DETAILS

USD 3,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.